FDA should provide better education about biosimilar drugs on the agency’s web site dedicated to biosimilars, a patient advocacy group said.
A pharmacist organization is among the supporters of a new Medicare Part D proposal, which calls for a 7-day supply limit on opioid prescriptions.
FDA is adding a Boxed Warning, its most prominent warning, on a liver disease medicine.
A patient advocacy group is criticizing the hefty price tag of a new treatment for blindness.
Patients with systemic lupus erythematosus often self-manage their corticosteroid medication without the consent of their healthcare providers, according to a recent multicountry survey.
While hospitals continue to face IV saline shortages after two hurricanes significantly damaged infrastructure in Puerto Rico, the situation should improve early this year.
FDA expanded the indication on cabozantinib (Cabometyx, Exelixis) to treat patients with advanced renal cell carcinoma (RCC).
Soon after FDA approved a novel device to treat opioid use disorder, FDA approved the first and only once-monthly injectable buprenorphine formulation to treat moderate to severe opioid use disorder (OUD).
Because of the impact of Hurricanes Maria and Irma on Puerto Rico’s infrastructure and drug manufacturing, hospitals face an ongoing shortage of IV fluids manufactured there.
FDA granted a new indication to a device that can help reduce the symptoms of withdrawal from the prescription pain drugs.